We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2017 15:20 | Looking a bit more lively on Nasdaq. Wonder if this is the post meetings buying or anticipation of news? | waterloo01 | |
17/1/2017 09:53 | Yep, a news driven stock needs feeding. If there's no news maybe directors will use the opportunity to buy. It doesn't look like they'll hit the option targets unless they pull that C.Diff deal out of the bag.... we know it must be in there but we don't know how big the bag is or even how many bags there are :-) | freemoney1 | |
17/1/2017 09:25 | Now the US holiday season is over....time for some news? | waterloo01 | |
13/1/2017 17:18 | Summit Therapeutics Plc breached its 50 day moving average in a Bullish Manner : SUMM-GB : January 12, 2017 | chrisatrdg | |
12/1/2017 20:50 | Ah ha ... many thanks sir | hugus maximus | |
12/1/2017 18:12 | 20K of "bought" was a rollover, Hugus. Daily movements like this are of no consequence. | freedosh | |
12/1/2017 16:58 | Some bizarre MM shenanigans on AIM today ... supposedly 26,500 shares bought and 16,600 sold, yet a considerable fall in SP? As a good friend once said "Investing on AIM is a little like playing poker ... but although you have no idea what the other players have been dealt, they can all see your hand!" © Del boy | hugus maximus | |
12/1/2017 13:16 | I was using current valuations, which should take into account current sentiment. But you may have a point that subdued sentiment may have an impact on the rate of the rise on good results, but long term value should eventually be realised. It will continue to be very interesting watching this biotech/pharma evolve. GLA | freemoney1 | |
12/1/2017 12:02 | Although I share your optimism for SUMM's future, freemoney, direct comparisons with what Sarepta's share price did on P2 results have to take into account the conditions appertaining at the time of their rise. Market sentiment for Biopharmas was bubbling high at the time and sadly it isn't now. Nevertheless, we should see a substantial multi bag, even with sentiment lower. | luminoso | |
12/1/2017 11:15 | Freemoney, A nice synopsis for us,so any nervous holders should feel happier and hold, Its only sells that drop the price, | abergele | |
12/1/2017 10:21 | CM, all subject to a shareholder vote as Glyn reminded shareholders at a previous AGM when the takeover fear question was raised. I think most shares are held by well informed shareholders now who realise the full value potential here. Any DMD success will see our market share price go well beyond £10 IMO......or at least it should do! If you look at our market valuation compared to Sarepta and that Sarepta massively jumped up in value on positive phase 2 results you can calculate that maybe we'll hit around £32. But that's only valuing us the same and remember Sarepta can only help up to 13% of the population, whereas we are aiming for 100%. If the market appreciates that then £32 per share will be low IMHO. The latest presentation highlights the path to market for Ezutromid. They are that confident and close to transformational results they see the need to map out the whole story and aim to get the treatment to DMD families as soon as possible. Only months until those first results start coming through now. GLA | freemoney1 | |
12/1/2017 09:35 | Sorrento, Yes I was in my conclusions acclaimed your trade as a buy,Many thanks for making matters clearer,,,it's a shame in this day and age,they blame software etc, for the deviations in prices,,ie,if your trade is a buy,they adjust the spread automatically as to prove its orrigionality to the public,must be simple,if it's below mid,the spread drops momenterally before readjusting...does this not seem fair..and clearer to the other investors.gl with the buy,I'm out of pocket from my buys yesterday, but hey ,we are here for he longer shout.... | abergele | |
12/1/2017 08:31 | My trade is the 1st today and it's showing as a sell. | sorrento06 | |
11/1/2017 20:39 | We've broken throught the lower trailing dma today yet again,I do hope we can capitalise on this and not start selling from the start, we have a long journey to travel,and it would be nice to break away from the £1.70's and up to £2, again for starters.. gla lth's | abergele | |
11/1/2017 18:46 | FM, what are the chances of SRPT swallowing us up and issuing us with lets say £10 a share and some of their shares ? IMHO I wouldn't have thought they would want to be overshadowed by SUMM in the long term. | cautiousmoney | |
11/1/2017 18:23 | When you think Trump, you must always bare in mind that he's a dealmaker at heart. Pharma will be forced to be transparent in pricing and what they can charge will be limited (probably about time). Must have an effect on the larger pharma which rely on some huge profit margins. On the other hand, he wants to make it easier and faster to get drugs to market. The net effect (in my view) on companies like Summit, is that they will find it cheaper and quicker to develop drugs, but they will have to cap (or at least have a very good rational) for the top end drug price expectations. Pharma will either have to get used to lower profits or grow sales by developing more drugs and treatments, and that should increase their appetite for late stage drugs. Edit: On pricing, in terms of Summit, we will come in alot lower than the current SRPT drug, and a such might be more isolated from the Trump fallout . A number of reasons. It's cheaper to produce/store etc, it's oral and if approved would be potentially available to 100% of patients, so can afford to be very competitively priced, even for Trump. | waterloo01 | |
11/1/2017 17:34 | Now clear thanks waterloo01 & I agree about Trump really scary watched him live on CNN. | chrisatrdg | |
11/1/2017 17:23 | They aren't doing a presentation as such but no doubt they pull in out for meetings. Not noticed anything new but haven't compared. Trump's quite something! | waterloo01 | |
11/1/2017 17:13 | Following waterloo01 earlier posting & link again below is there anything new certainly there are are posters but do they show any new science also I think it is the first time such a presentation has been issued but no RNS. | chrisatrdg | |
11/1/2017 11:53 | Good share price reaction on both sides of the pond. But I see there is still a massive valuation difference between Sarepta and Summit. Market capitalisations : Summit : $110.53m Sarepta : $2,149.57m Once Ezutromid and Utrophin upregulation is proven (Q2/3) we should at least equal Sarepta in valuation but many would argue that since we can treat 100% of the population and we retain the most valuable market (US) we should exceed Sarepta's valuation. That's some upside!!!! We also have the second programme, C.Diff, which is due to deliver value to shareholders in the near term. Hopefully new investors with deep pockets are realising all this and our share price will continue to correct. GLA | freemoney1 | |
11/1/2017 10:47 | I see exactly what you're saying H.A. When the Summit share price leapt up in response to the Sarepta / Summit licensing deal, there were folk on message boards in the states suggesting the exact same thing was going on. Or indeed maybe we're watching the effects of news breaking in certain quarters before it's made public. Whatever it is - the effect is not insignificant and most welcome! | hugus maximus | |
10/1/2017 23:47 | IMO Sarpeta share interest is a consequence of them finally rolling out eteplirsen after a slow start and the announcement to that effect (a couple of days ago) brings their FDA promise toward some sort of actual fruition. Hence Sarepta's slow drop in share price in the months after the FDA approval date, was due to expectations not being met quickly enough (both in demand and supply). There were many reports of difficulties until this weeks announcement that things had turned around. I wonder if their pipe line Exon 51 is too much a part of the distant future to produce todays share price effect ... although will perhaps have endorsed their position slightly? Maybe Summit are riding on Sarepta's coat tails and the market has turned from hot to cold to warm again about wariness of DMD market in general? Let's hope that the improved eteplirsen pipeline holds for a while, allowing Summit to come in with some serious guns blazing and their shares being bought on their own terms. IMO If Summit can prove with their empirical full comprehensive clinical testing that Ezutromid stands up to the plate (as opposed to the more subjective eteplisen research work which still casts elements of doubt), the DMD market will finally and categorically be banging at their door. EDIT - unless I've missed something majorly significant announced at the San Fran Health Conference which made Summit's shares move up independently last night? | hugus maximus | |
10/1/2017 19:55 | $12.50 next waypoint. Wonder if any of it has to do with any of the meetings or realisation of the value now SRPT are earning ahead of expectations, just with Exon 51? | waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions